ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 555 participants.

Also called NCT05746559

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 555 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05746559
  • EudraCT 2022-501802-36
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, China, France, Germany, Hong Kong SAR China, India, Israel, Italy, Japan, Netherlands, Poland, South Korea, Spain, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05746559. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-06 (actual); primary completion 2025-10-07 (actual). Results posted on 2026-10-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Acronym
ARTEMIS
Condition
Cardiac Disease
Condition
Cardiopulmonary Bypass
Intervention (Drug)
Placebo
Intervention (Drug)
Ravulizumab
Lead sponsor
Alexion Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05746559
Content hash
12ab31c4c470df5795d53147567190cbd8fb9c248e6cf442f2710a2579c5a715